Pharmafile Logo
Pharmafocus logo
Advanced Search

Lilly/Incyte RA drug bests Humira in Phase III trial

November 10, 2015
Research and Development Humira, baricitinib, lilly, phase III, rheumatoid arthritis

Eli Lilly says its investigational therapy baricitinib outperformed AbbVie’s Humira after 12 weeks in a late-stage study of people with …

News
ABPI

ABPI welcomes science budget inquiry findings

November 10, 2015
Manufacturing and Production, Research and Development ABPI, Comprehensive Spending Review

The UK pharma trade body, the ABPI, has welcomed the findings of the Science and Technology Committee’s inquiry into the …

News
Westminster

All Party Parliamentary Group for Life Sciences CSR letter to the Chancellor, Business Secretary and Science Ministers

November 10, 2015
Manufacturing and Production, Research and Development Chancellor, Comprehensive Spending Review, George Osborne

Dear Mr Osborne,Ahead of the forthcoming Comprehensive Spending Review I am sure you will have received many letters from across …

Feature
Janssen image

Janssen buys licence to diabetes and obesity drugs from Hanmi

November 10, 2015
Manufacturing and Production, Research and Development Janssen, diabetes, hanmi

Janssen could spend up to a billion dollars to buy for novel clinical stage biologics to treat diabetes and obesity. …

News

FDA warnings create woe for Indian drugmakers

November 10, 2015
Manufacturing and Production CGMP, Dr Reddy's, Dr. Reddy's, FDA, India, Sun Pharma, manufacturing, production

Recent enforcement action has taken its toll on the fortunes of several Indian pharmaceutical manufacturers, with Sun Pharmaceuticals and Dr. …

News
flu vaccine

Sanofi Pasteur ‘actively exploring’ universal flu vaccine

November 10, 2015
Manufacturing and Production, Research and Development SEEK, Sanofi Pasteur, influenza, universal flu vaccine

Sanofi Pasteur is developing a universal, cross-reactive antigen against seasonal and pandemic influenza, the company has revealed.The French firm presented its …

News

Jardiance scores more cardiovascular outcomes data

November 10, 2015
Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …

News

Health minister criticised for blocking Off-Patent Drugs Bill debate

November 9, 2015
Research and Development, Sales and Marketing Alistair Burt, Breast Cancer Now, MS Society, Off-Patent Drugs Bill

A Parliamentary Bill backing the wider use of off-patent drugs has been kicked into the long grass after the Government …

News
EMA HQ

EMA concludes HPV vaccines do not cause CRPS or POTS

November 9, 2015
Sales and Marketing EMA, HPV, HPV vaccine, PRAC, complex regional pain syndrome, drug safety, postural orthostatic tachycardia syndrome

The European Medicines Agency says there is no evidence from a detailed scientific review of reports linking complex regional pain …

News
UNITAID

Medicines Patent Pool to include hep C and TB drugs

November 9, 2015
Sales and Marketing Medicines Patent Pool, affordable drugs, hep C, hepatitis, hepatitis C, medicines access, tuberculosis

The Medicines Patent Pool has expanded to include a mandate to make treatments for hepatitis C and tuberculosis affordable and …

News
clinical trials

Governments and industry ‘combining to stall drug development’

November 9, 2015
Research and Development, Sales and Marketing BMJ, R&D, drug development

Both government and industry practices are responsible for the innovation deficit in the pharmaceutical sector, meaning that “the majority of …

News
Pfizer logo

Pfizer to double patient assistance allowance in the US

November 9, 2015
Sales and Marketing Drug pricing, Pfizer

Pfizer says it will double the allowable income level for its RxPathways patient assistance program in the US with immediate …

News
gsk_hq

GSK asthma drug Nucala gets FDA approval

November 6, 2015
GSK, Nucala, asthma, eosinophils, mepolizumab

GlaxoSmithKline has received approval from the FDA for Nucala as an add-on maintenance treatment of patients with severe asthma aged …

News
boehringers_current_board

Boehringer announces board changes, chairman’s retirement

November 6, 2015
Medical Communications, Sales and Marketing

Boehringer Ingelheim has announced that Professor Andreas Barner will retire as chairman of the Board of Managing Directors on 30 …

Appointment

UK doctors embracing technology, but not for their patients, survey reveals

November 6, 2015
Medical Communications, Research and Development

A global online survey of doctors released by market research agency Cello Health Insight has indicated that although UK doctors …

News
dollar-544956_1280

Top 5 pharma companies’ Q3 results

November 6, 2015
Medical Communications, Sales and Marketing financial results, revenue, sales

The leading pharma players have been able to report largely positive financial results to their shareholders in the third quarter …

Feature
astrazeneca image

AstraZeneca acquires ZS Pharma for $2.7bn, announces Q3 results

November 6, 2015
Medical Communications AstraZeneca, M&A, MA, ZS Pharma, ZS-9, acquisitions, financial results, hyperkalaemia, mergers

AstraZeneca has announced its acquisition of ZS Pharma for an all-cash total of $2.7 billion. In the latest mega-money deal …

News
Sanofi logo

Sanofi buys in new diabetes drug

November 6, 2015
Medical Communications, Research and Development, Sales and Marketing Lexicon Pharma, SGLT2, SGLT2 inhibitors, Sanofi, sotagliflozin

Sanofi has paid an initial $300 million for collaboration and license agreement to develop sotagliflozin, one of a newer class …

News
Olivier Brandicourt

Brandicourt sets out Sanofi’s long-term vision

November 6, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, olivier brandicourt, pharma strategy

Sanofi has pledged to plough the money saved from its business restructure into R&D investment, to bring 18 new products …

News
nsclc_merck_pfizer

Merck and Pfizer begin new Phase III avelumab trial in lung cancer

November 5, 2015
Medical Communications, Research and Development Merck, Pfizer, avelumab, lung cancer, non-small cell lung cancer

Merck and Pfizer have commenced an international Phase III study of the investigational cancer immunotherapy avelumab in patients with non-small …

News
The Gateway to Local Adoption Series

Latest content

Study explores genomic testing approach for unexplained infertility

May 14, 2026

Celtic Renewables receives £7m to develop bio-based solvents

May 14, 2026

Synnovis and SOPHiA GENETICS expand liquid biopsy testing in NHS cancer care

May 13, 2026

MHRA to establish Northern Ireland hub for life sciences sector

May 13, 2026

Shilpa Medicare signs manufacturing deal with NXI Therapeutics

May 12, 2026